<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152084</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00049</org_study_id>
    <secondary_id>2016-002961-79</secondary_id>
    <nct_id>NCT03152084</nct_id>
  </id_info>
  <brief_title>The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.</brief_title>
  <acronym>DAPASALT</acronym>
  <official_title>DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by
      Type 2 Diabetes Mellitus status and kidney function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">December 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hr sodium excretion</measure>
    <time_frame>up to 5 days</time_frame>
    <description>To investigate change in 24-hr sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with Type 2 Diabetes Mellitus with preserved or impaired renal function and in non-diabetics with impaired renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hr glucose excretion</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Average change in 24-hr glucose excretion from average Baseline values to average values at Day 2 to 4; from average Baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24-hr systolic blood pressure</measure>
    <time_frame>up to 19 days</time_frame>
    <description>Change in mean 24-hr systolic blood pressure from Baseline to Day 4; from Baseline to end of treatment (Day 13); and from end of treatment (Day 13) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hr sodium excretion from baseline to end of treatment and during follow-up</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Average change in 24-hr sodium excretion from average Baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma volume</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Change in plasma volume from Baseline to Day 4; from Baseline to end of treatment (Day 14); and from end of treatment (Day 14) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in extracellular volume</measure>
    <time_frame>up to 18 days</time_frame>
    <description>Change in extracellular volume from Baseline to Day 4; from Baseline to end of treatment (Day 14); and from end of treatment (Day 14) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hr urine albumin:creatinine ratio (UACR)</measure>
    <time_frame>up to 15 days</time_frame>
    <description>Average change in mean 24-hr urine albumin:creatinine ratio (UACR) from average Baseline to Day 4; and from average Baseline values to average end of treatment values (Day 12 to 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of dapagliflozin</measure>
    <time_frame>At pre-dose (day 4)</time_frame>
    <description>Dapagliflozin plasma concentration pre-dose on Day 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of dapagliflozin</measure>
    <time_frame>At pre-dose, 1h, 2h, 4h post-dose (day 14)</time_frame>
    <description>Dapagliflozin plasma concentration pre-dose and post-dose on Day 14.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Kidney Function Tests</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2DM subjects with an eGFR (CKD-EPI) between &gt;90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between &gt;85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between &gt;75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Female and/or male aged between 18 years and ≤80 years

          -  In the diabetic arms - a diagnosis of T2DM with HbA1c ≥6.5% (≥48 mmol/mol) and &lt;10%
             (&lt;86 mmol/mol); and eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 or between &gt;90
             and ≤130 mL/min/1.73m2 for patients aged 59 years or younger, between &gt;85 and ≤130
             mL/min/1.73m2 for patients aged 60 to 69 years, and between &gt;75 and ≤130 mL/min/1.73m2
             for patients aged 70 years or older at the Screening Visit (Visit 1)

          -  In the non-diabetic arm, HbA1c &lt;6.5% (&lt;48 mmol/mol) and an eGFR (CKD-EPI) between ≥25
             and ≤50 mL/min/1.73m2 at the Screening Visit (Visit 1)

          -  Patient specific optimal antihypertensive dose of an angiotensin receptor blocker at
             least 6 weeks before study treatment

          -  In the diabetic arms an appropriate stable dose of metformin, or sulphonylurea, or
             metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks before study
             treatment

          -  Stable urinary sodium excretion on 2 successive 24-hr urinary sodium excretion
             measurements.

        Exclusion Criteria:

          -  Diagnosis of Type 1 Diabetes Mellitus

          -  Any of the following cardiovascular/vascular diseases within 3 months prior to signing
             the consent; myocardial infarction, cardiac surgery or revascularization, unstable
             angina, unstable heart failure, heart failure NYHA Class IV, transient ischemic attack
             or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia

          -  Symptoms/complaints suggestive of established neurogenic bladder and/or incomplete
             bladder emptying

          -  History of bladder cancer, diagnosis of polycystic kidney disease, history or current
             lupus nephritis or unstable or rapidly progressing renal disease

          -  UACR &gt;1000 mg/g at screening

          -  Current/chronic use of the following medications: any anti-diabetic medication with
             the exception of metformin and sulphonylurea, angiotensin converting enzyme
             inhibitors, oral glucocorticoids, non-steroidal anti-inflammatory drugs, immune
             suppressants, chemotherapeutics, antipsychotics, tricyclic antidepressants and
             monoamine oxidase inhibitors.

          -  Receiving immunosuppressive or other immunotherapy for primary or secondary renal
             disease within 6 months prior to screening

          -  Current treatment or treatment within the last 2 weeks prior to screening with
             diuretics including loop diuretics, thiazides, and mineralocorticoid antagonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almelo</city>
        <zip>7600</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

